When did apotex receive usa approval for ruxolitinib?

Apotex received US FDA approval for its ruxolitinib tablets in 2021 for the treatment of adult patients with polycythemia vera [1] DrugPatentWatch.com reports that the Canadian generic pharmaceutical company Apotex submitted a Abbreviated New Drug Application (ANDA) for Ruxolitinib tablets to the United States Food and Drug Administration (FDA). The FDA granted final approval for Ruxolitinib tablets to Apotex on February 19, 2021, [2]. Ruxolitinib is also approved by other health agencies, such as the European Medicines Agency (EMA) for the treatment of myelofibrosis [3], another type of myeloproliferative neoplasms.

Sources:

[1] https://www.drugpatentwatch.com/patent/US10649211
[2] https://www.drugpatentwatch.com/nda/2021-022511
[3] https://www.drugpatentwatch.com/patent/US10351123